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Abstract
Background/Objectives—γ-Tocopherol has unique properties that protect against nitrogen 
oxide-mediated cellular damage. To elucidate the potential role of γ-tocopherol in the aging 
process, we examined the associations of serum γ-tocopherol levels with all-cause and cause-
specific mortality.
Subjects/Methods—Among participants in the biorepository subcohort of the Multiethnic 
Cohort Study, pre-cancer diagnostic serum γ-tocopherol levels were measured in a subset of 3904 
men and 4461 women. Of these, 22.7% of men and 13.5% of women died during a mean follow-
up time of 9.6±2.6 years. Hazard ratios (HRs) and 95% confidence intervals (95%CIs) for 
mortality associated with γ-tocopherol were estimated by Cox proportional hazards regression.
Results—Positive associations of serum γ-tocopherol with all-cause, cancer and cardiovascular 
disease mortality (CVD) (Ptrend<0.05) were detected after adjusting for age, race-ethnicity and 
serum cholesterol levels. The respective HRs (95%CIs) for the highest versus the lowest sex-
specific γ-tocopherol quartile were 1.43 (1.17–1.74), 1.79 (1.22–2.64), and 1.52 (1.10–2.11) for 
men and 1.58 (1.25–2.00), 1.59 (1.05–2.41), and 1.59 (1.07–2.37) for women. Associations 
remained significant for all-cause mortality among women after further adjusting for smoking 
variables and history of cancer, CVD, diabetes, and hypertension at cohort entry (highest vs. 
lowest γ-tocopherol quartile: HR=1.38; 95%CI=1.08–1.75; Ptrend= 0.005). Overall, associations 
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with all-cause mortality were consistent across race/ethnicity and were significant in three of ten 
sex-specific racial/ethnic groups in the fully adjusted models with no interactions between 
ethnicity and γ-tocopherol.
Conclusions—The positive association between γ-tocopherol and mortality suggests a potential 
physiological role for γ-tocopherol in response to pathological conditions.
INTRODUCTION
The tocopherols are important agents that prevent cellular oxidative damage and are thought 
to protect against the development of cancer and other aging-related diseases [1, 2]. 
Although α-tocopherol has the highest level of vitamin E bioactivity of all the tocopherols 
[3] and, consequently, has been the target of the most research over the years, animal studies 
have shown that other tocopherols also play a significant role in inhibiting tumor formation 
independent of vitamin E bioactivity [2]. In particular, γ-tocopherol has been identified as a 
key carcinogenesis modifier and cellular antioxidant that limits damage to cells resulting 
from the enzymatic production of nitric oxide (NO), a mediator of inflammation through its 
oxidation products [4–6]. Paradoxically, γ-tocopherol at high concentrations can also 
enhance cellular NO synthesis resulting in an enhanced cellular immune response and 
potentially increased oxidative damage [4].
The Institute of Medicine (IOM) has identified a concentration of 5.16 μg/mL (12 μM) α-
tocopherol in blood as sufficient to meet vitamin E requirements in humans with respect to 
acute consequences of vitamin E deficiency. The IOM further concludes that only α-
tocopherol is required for vitamin E function and that there is inadequate evidence to 
recommend a requirement for γ-tocopherol [7]. However, the IOM report points out the 
need for more research to determine the levels and types of tocopherols that are important 
for optimal nutrition and their mechanisms in the prevention of aging related chronic 
diseases. In particular, serum levels of γ-tocopherol appear to be independent of dietary 
intake and physiologically regulated [8], possibly as a consequence of chronic inflammation. 
This was suggested by the positive associations of γ-tocopherol with circulating C-reactive 
protein (CRP) and urinary isoprostane (both indicators of chronic inflammation) [9] as well 
as by animal and cell studies showing γ-tocopherol levels increase in response to 
inflammation [10, 11]. Previous work also found that γ-tocopherol was positively associated 
with various disease states and risk factors that are associated with inflammation, such as 
diabetes [12], Alzheimer’s Disease [13], smoking [14], obesity [15] and poor diet [16]. 
Further, infection is often a source of chronic inflammation and it has been reported that 
elevated γ-tocopherol levels are associated with higher clearance of anal human 
papillomavirus infection [17].
Epidemiological evidence regarding associations of γ-tocopherol with aging and the 
etiology of aging related diseases is limited and results are equivocal. While some studies 
reported inverse associations of γ-tocopherol with certain types of cancers [18–20], null 
[21–23] or positive associations have been found in others [20, 24]. Further, a nested case-
control study with 39,242 Japanese subjects found that serum γ-tocopherol levels were 
inversely associated with ischemic stroke mortality in men but positively associated with 
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hemorrhagic stroke mortality in women [25]. However, to our knowledge, no study to-date 
has assessed the relation between γ-tocopherol and overall risk of death and its consistency 
across racial/ethnic groups. Because of its unique paradoxical relationship and the broad 
array of evidence from basic science studies as well as epidemiologic associations, we 
hypothesize that elevated γ-tocopherol levels generally reflect increased risk of premature 
mortality, which may in turn serve as an indicator of adverse physiologic conditions such as 
chronic inflammation and heightened systemic and/or tissue-specific oxidation. Support for 
this concept was further suggested by a recent cross-sectional study using a nationally 
representative sample showing that adults with γ-tocopherol levels in the highest quartile 
(75–100th percentile) had much shorter telomere length (a biomarker for biological aging) 
than those at the lowest quartile (0–25th percentile), accounting for approximately three 
years of additional biological aging [26]. Thus, the current study examined the associations 
of serum levels of γ-tocopherol with all-cause mortality, cancer mortality, and 
cardiovascular disease (CVD) mortality among men and women with white, African 
American, Native Hawaiian, Japanese American, and Latino ancestry who participated in 
the biorepository subcohort of the Multiethnic Cohort (MEC) Study.
PARTICIPANTS AND METHODS
Study Population
The MEC is a prospective cohort study assembled in Hawaii and Los Angeles during 1993–
1996 funded by the National Cancer Institute to investigate the association of dietary, 
lifestyle, and genetic factors with cancer incidence. Details on recruitment and baseline 
demographic information have been described previously [27]. Briefly, subjects from five 
ethnic groups (white, African American, Native Hawaiian, Japanese American, and Latino) 
were identified through drivers’ license files, voter registration lists in Hawaii and Medicare 
files in California and recruited by mailing a self-administered, 26-page questionnaire that 
included questions on anthropometric measures, medical history, family history of cancer, 
lifestyle factors, and a food frequency questionnaire of over 180 items and dietary 
supplements. The validity of the dietary questionnaire was confirmed in a calibration study 
using three 24-hour dietary recalls [28]. A total of 215,251 men and women aged 45 to 75 
years were included at baseline representing the general target population as verified by a 
comparison of the cohort distributions with corresponding census data for the two 
geographical areas [27]. The study protocol was approved by the Institutional Review 
Boards of the University of Hawaii and the University of Southern California and informed 
consent was obtained from all subjects.
The MEC biorepository was established primarily during 2001–2006 by asking surviving 
cohort members residing in the catchment area of the University of Hawaii and University of 
Southern California to provide blood and urine specimens [29]. A total of 67,594 cohort 
members (approximately 32% of original MEC members) contributed to the biorepository 
and of all blood samples collected, 18% were analyzed for biomarkers. Participants were 
free of cancer at the time when blood and urine were collected. When comparing the 
characteristics of individuals who provided specimens with those who did not, participants 
were younger by an average of three years, had more education, and were less likely to be 
Chai et al. Page 3
Eur J Clin Nutr. Author manuscript; available in PMC 2019 December 27.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
current smokers. However, there were no substantial differences between the two groups in 
several demographic characteristics and cancer risk factors including body mass index 
(BMI), dietary fat and vegetable intake, physical activity, and family history of cancer 
suggesting that the biorepository participants are broadly representative of all cohort 
members. Mortality from cancer and other causes was available through linkages with death 
certificate files in both states. For cohort members who moved to other states, information 
on deaths was obtained from the National Death Index [27, 30].
Serum Assays
A panel of biomarkers were assayed in the MEC biorepository subcohort that included 
controls from nested cancer case-control studies. Lipid-soluble micronutrients were assessed 
in 8,664 individuals from this subcohort. After excluding participants with invalid biomarker 
measurements, the final analysis cohort consisted of 8,365 participants (3904 men and 4461 
women). All serum samples were collected after an overnight fast, stored at −80°C 
immediately after blood collection, and had not been previously thawed before extraction to 
minimize the outcome variations due to storage conditions such as temperature and storage 
duration from collection to processing. Serum concentrations of tocopherols were analyzed 
using high-pressure liquid chromatography with photodiode-array detection according to our 
earlier protocol [31, 32]. The β- and γ-tocopherols were measured together. Given that β-
tocopherol comprises only a tiny fraction of total tocopherols, the combined values represent 
predominantly γ-tocopherol. Based on nine triplet pooled samples prepared for quality 
control, the respective within- and between-batch coefficients of variation were 2.2±2.0% 
and 5.9±4.7% for β- and γ-tocopherols combined.
Statistical Analyses
Serum γ-tocopherol levels were categorized into quartiles for men and women, separately. 
Cox proportional hazards regression models were used to estimate hazard ratios (HRs) and 
95% confidence intervals (95%CIs) for associations of γ-tocopherol with all-cause, cancer, 
and CVD-specific mortality among men and women. Deaths due to injuries (0.3% of all 
deaths) were excluded from all-cause mortality. Survival time was defined from the date of 
blood draw until death or the end of follow-up on December 31, 2013. For cancer and CVD-
specific models, participants who had died from other causes were censored. Two models 
were estimated: Model 1 (minimally adjusted model) only included age at blood draw, race/
ethnicity (as a strata variable: white, African American, Native Hawaiian, Japanese 
American, and Latino) and serum cholesterol levels while Model 2 (fully adjusted model) 
further included smoking variables and history of cancer, CVD (heat attack, angina, stroke), 
diabetes, and hypertension at cohort entry (before blood draw). The adjustment for serum 
cholesterol levels in both models was because previous research found that tocopherols and 
cholesterol levels were highly correlated [19]. The adjustment for smoking was based on a 
comprehensive smoking model that was developed for a lung cancer study in the MEC [33]. 
The smoking model explicitly included average number of cigarettes; average number of 
cigarettes squared; indicator variables for former and current smokers; number of years 
smoked (time-dependent); and number of years since quitting (time-dependent). We also 
considered BMI, alcohol use and season of blood draw as covariates but did not include 
them in the final models because they did not alter the risk estimates. Sensitivity analyses 
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were performed after excluding participants who died within one year after blood draw. 
Research evidence showed a direct relationship between CRP and mortality [34] and γ-
tocopherol was positively associated with CRP [9]. Thus, we added CRP (log-transformed 
values) in Model 1 to determine if γ-tocopherol contributed any information beyond CRP to 
predict mortality (Model 3).
In order to determine whether the associations between γ-tocopherol and mortality, if 
present, were consistent across racial/ethnic groups in MEC, analyses were repeated 
separately by sex-specific racial/ethnic groups. Due to the relatively small number of 
participants in some racial/ethnic groups, sex-specific tertiles of γ-tocopherol (for the 
overall study population of men and women, respectively) were used in these analyses. 
Interaction terms between serum γ-tocopherol levels and race/ethnicity in relation to 
mortality were estimated. As supplementation with large doses of α-tocopherol may 
significantly depress γ-tocopherol concentrations in the serum [9], we performed sensitivity 
analyses by excluding participants taking vitamin E supplements (mainly containing α-
tocopherol) at cohort entry and participants whose serum α-tocopherol concentrations were 
≥18 ug/mL. Further, we also assessed the association of serum α-tocopherol levels 
(categorized into sex-specific quartiles) with all-cause mortality using Cox proportional 
hazards regression to determine whether the association for α-tocopherol was similar to that 
for γ-tocopherol. The proportionality assumption was tested by Schoenfeld residuals and 
was found to be valid. SAS statistical software version 9.4 (SAS Institute, Inc., Cary, North 
Carolina) was used to conduct all analyses. All tests were two-sided, and P < 0.05 was used 
as the critical value for statistical significance.
RESULTS
This analysis included 8365 participants (3,904 men and 4,461 women); of these, 1,489 (886 
men [22.7%] and 603 women [13.5%]) had died during a mean follow-up time of 9.6±2.6 
years. The racial/ethnic distribution for the study population was 8% white, 28% African 
American, 26% Native Hawaiian, 30% Japanese American, and 8% Latino, which differed 
from the original parent MEC biorepository subcohort due to the selection process of 
matching controls to case characteristics. The mean age at blood draw of participants in the 
current study was 68.3 ± 8.5 years, which was similar to the MEC biorepository cohort. 
Major disease-related causes of death were cancer (30.5%), major CVD (35.5%), 
respiratory/pulmonary diseases (4.9%), diabetes (2.1%), and infectious disease (1.0%). 
These rates were comparable to those observed in the original MEC (data not shown). 
Differences in age, race/ethnicity, BMI, smoking related variables, alcohol use, 
hypercholesterolemia and history of cancer, CVD, diabetes or hypertension were observed 
between participants who died and participants who remained alive during the follow-up. γ-
Tocopherol levels were positively associated with smoking, adiposity, hypercholesterolemia, 
and history of cancer, CVD, diabetes, or hypertension and inversely associated with 
moderate/vigorous physical activity and α-tocopherol concentrations (Table 1).
Serum γ-tocopherol levels were positively associated with all-cause mortality in both men 
and women after adjusting for age at blood draw, race/ethnicity and serum cholesterol levels 
(men: Ptrend=0.0005; women: Ptrend<0.0001). The mortality risk was approximately 40% 
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higher among men and 60% higher among women for the highest versus the lowest quartile 
of γ-tocopherol (men: HR=1.43, 95%CI=1.17–1.74; women: HR=1.58, 95%CI=1.25–2.00). 
The association remained significant for women when the model was additionally adjusted 
for history of cancer, CVD, diabetes, and hypertension and smoking variables at cohort entry 
(the highest versus the lowest γ-tocopherol quartile for women: HR=1.38, 95%CI=1.08–
1.75; Ptrend= 0.005). Although attenuated, the relation between γ-tocopherol and all-cause 
mortality remained significant when CRP was included in Model 1 (the highest versus the 
lowest quartile for men: HR=1.34, 95%CI=1.09–1.63; Ptrend= 0.006; for women: HR=1.45, 
95%CI=1.14–1.83; Ptrend= 0.001) (Table 2). Further, γ-tocopherol and α-tocopherol 
appeared to have opposite associations with mortality risk; while positive associations were 
observed for γ-tocopherol with all-cause mortality among both men and women, higher 
serum α-tocopherol levels were more likely to be associated with lower risk of mortality 
(all-cause) particularly for women in the age, ethnicity, and cholesterol adjusted models 
(Figure 1).
Serum γ-tocopherol levels were also positively associated with cancer mortality (Table 3) 
among men (Ptrend=0.005) and women (Ptrend= 0.006) after adjusting for age at blood draw, 
ethnicity, and serum cholesterol. Mortality risk was approximately 80% higher among men 
(HR=1.79, 95%CI=1.22–2.64) and 60% higher among women (HR=1.59, 95%CI=1.05–
2.41) for the highest versus the lowest quartile of γ-tocopherol. Although the association 
was attenuated after further adjusting for history of major diseases (cancer, CVD, diabetes, 
hypertension) and smoking variables, mortality risk was 80% higher for the second highest 
compared to the lowest quartile among men (HR=1.83, 95%CI=1.26–2.67). Similarly, 
positive associations were observed between γ-tocopherol and CVD mortality risk among 
men (Ptrend=0.01) and women (Ptrend=0.01) in the age, ethnicity and cholesterol adjusted 
models with an approximately 50 – 60% higher risk for the highest relative to the lowest γ-
tocopherol quartile (men: HR=1.52, 95%CI=1.10–2.11; women: HR=1.59, 95%CI=1.07–
2.37). Likewise, the associations for γ-tocopherol with CVD mortality risk were attenuated 
for both men and women in the fully adjusted models (Table 3). In addition, results did not 
change materially from the overall models after excluding participants who died within one 
year after blood draw (Supplementary Table 1) as well as by excluding participants taking 
vitamin E supplements at cohort entry and participants having serum α-tocopherol 
concentrations ≥18 ug/mL (Supplementary Table 2).
After analyses were repeated separately by sex-specific racial/ethnic groups, positive 
associations for γ-tocopherol with all-cause mortality were observed in six out of ten sex-
specific racial/ethnic groups (white, Japanese, and African American men and white, 
African American and Native Hawaiian women) in the age and cholesterol adjusted models 
(Ptrend<0.05) and none of the HRs in the other ethnic groups indicated significant association 
(data not shown). The associations remained significant for white men (Ptrend=0.01), white 
women (Ptrend=0.03) and Native Hawaiian women (Ptrend=0.01) in the fully adjusted models 
(Supplementary Table 3). Overall, the associations of γ-tocopherol with all-cause mortality 
were consistent across racial/ethnic groups in the study. No interactions between ethnicity 
and γ-tocopherol in relation to mortality were observed.
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DISCUSSION
In the current study, serum γ-tocopherol levels were positively associated with all-cause 
mortality, as well as cancer and CVD-specific mortality among men and women adjusting 
for age, ethnicity and serum cholesterol levels after close to ten years of follow-up. The 
associations remained significant for all-cause mortality among women after further 
adjustment for history of major diseases such as cancer, CVD, diabetes, and hypertension 
and smoking variables at cohort entry. Sub-group analyses of the associations between γ-
tocopherol and all-cause mortality were significant for six out of ten sex-specific racial/
ethnic groups in the minimally adjusted models and remained significant for three of these 
groups in the fully adjusted models without interactions between ethnicity and γ-tocopherol.
A limited number of studies so far have examined the association between γ-tocopherol and 
mortality and the results are conflicting. Nagao et al. reported that serum γ-tocopherol was 
inversely associated with ischemic stroke mortality among men but positively associated 
with hemorrhagic stroke mortality among women from a large sample of Japanese 
participants (N=39,242) followed for 13 years [25]. Although Cooney et al. found no 
association of serum γ-tocopherol levels with all-cause or cancer specific mortality among 
colorectal cancer patients, they observed a strong association of CRP with both suggesting 
that inflammation may be a significant contributing factor to poor survival of cancer patients 
[34]. Although attenuated, the association between γ-tocopherol and all-cause mortality in 
our study remained significant when CRP was included in the minimally adjusted model. 
This may suggest that γ-tocopherol makes its own contribution beyond CRP to the 
prediction of mortality. As γ-tocopherol rises in response to inflammation [5, 35] despite its 
anti-inflammatory and protective effect against nitrogen oxide radicals, it may be elevated in 
individuals with serious disease who are at high risk of death as well as simultaneously 
function to reduce risk of death [10, 36].
Many biological effects of γ-tocopherol have been observed in vitro with potentially 
important biological and health consequences, including effects on sphingolipid metabolism, 
inflammation, nuclear peroxisome proliferator-activated receptor, neoplastic transformation, 
tumor cell proliferation, apoptosis, natriuresis, and immune function [37]. The results 
presented here are consistent with a hypothesis that elevated γ-tocopherol levels are 
predictors of all-cause, cancer and CVD mortality in the age, ethnicity, and cholesterol 
adjusted models, yet when further adjusted for the major risk factors for premature death 
such as smoking and history of major chronic diseases including cancer, CVD, diabetes, and 
hypertension the association is reduced significantly except for all-cause mortality for 
women. Although the association for all-cause mortality was not significant for men in the 
fully adjusted model, it nevertheless showed the same direction as that observed for women. 
Similarly, while significant associations between γ-tocopherol and all-cause mortality were 
observed for three out of ten sex-specific racial/ethnic groups in the fully adjusted models, 
the associations appeared consistent across race/ethnicity in the study. Our findings that 
serum γ-tocopherol levels were positively associated with mortality risk, whereas an inverse 
association with mortality was observed for α-tocopherol further suggest the potentially 
different physiologic properties and functions between α- and γ-tocopherols. In animals and 
cultured fibroblasts, γ-tocopherol levels rise in response to inflammatory signals, whereas in 
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contrast α-tocopherol appears to be a primary reactant against cellular oxygen-derived 
oxidants and a net rise in levels is not observed [5, 35].
To the best of our knowledge, this is the first study to examine the association of serum γ-
tocopherol levels and all-cause mortality in a population of five racial/ethnic groups. The 
large sample size and relatively long follow-up time enabled us to detect significant 
associations between γ-tocopherol and the risk of mortality. However, our study had 
limitations. The use of only one serum γ-tocopherol measurement may have misclassified 
exposure status for some individuals and, thereby, attenuated risk estimates. This is 
supported by a nested case control study of 88 colorectal cancer cases [38], where Kabat et 
al. reported higher significance for protective associations of pro-vitamin A carotenoids 
when repeated measurements of serum antioxidant levels were used. Interestingly a non-
significantly increased risk of approximately 50% was observed for elevated γ –tocopherol 
with colon cancer incidence [38]. In the current study, adjustment for season of blood draw 
to account for potential seasonal variations in γ-tocopherol levels did not significantly 
change the results; however, repeated measurements might have strengthened the association 
observed. In addition, we did not have updated information on some of the relevant variables 
such as smoking and supplement intake, for example supplemental vitamin E intake at the 
time of blood draw for all the study participants. Due to the selection for biomarker analysis, 
the prevalence of certain chronic diseases (e.g., diabetes) was low. Also chronic disease 
history was assessed at cohort entry and not thereafter. Lastly, there were discrepancies in 
racial/ethnic distributions between the current sample of participants and the original MEC 
population due to differential participation in the biorepository and selection into case-
control studies.
In conclusion, the novel results from the current study suggest that serum γ-tocopherol 
levels were significantly associated with all-cause as well as cancer and CVD-specific 
mortality among both men and women in the age, ethnicity and cholesterol adjusted models. 
The association remained significant for all-cause mortality for women after further 
adjustment for major risk factors of premature death such as smoking and history of major 
chronic diseases including cancer, CVD, diabetes, and hypertension. The observed positive 
association between γ-tocopherol and mortality risk suggests a potential role for γ-
tocopherol as a biomarker in response to pathological conditions and, therefore, more 
research should be conducted to assess its utility as a generalized marker for mortality risk in 
populations.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Associations of serum α-tocopherol and γ-tocopherol levels with all-cause mortality among 
men and women. Tocopherol levels were categorized into sex-specific quartiles (Q1-Q4) and 
the lowest quartile (Q1) was used as the reference quartile. Hazard ratios (HRs) and 95% 
confidence intervals (CIs) were plotted against the median level (μg/mL) of each α-
tocopherol or γ-tocopherol quartile. HRs and 95%CIs were estimated by Cox proportional 
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hazards regression adjusting for age at blood draw, race/ethnicity (as a strata variable) and 
serum cholesterol levels.
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Table 2.
HR and 95% CI for All-Cause Mortality by γ-Tocopherol Quartiles
γ-Tocopherol Quartiles (μg/mL) Median (μg/mL) Participants (N) Deaths (N) HR (95% CI)a Ptrenda
Men
Model 1b
Q1 (0.27–1.17) 0.96 973 198 1.00
Q2 (1.17–1.63) 1.39 974 211 1.18 (0.97–1.43)
Q3 (1.63–2.28) 1.92 968 223 1.25 (1.02–1.52)
Q4 (2.28–11.02) 2.86 972 237 1.43 (1.17–1.74) 0.0005
Model 2c
Q1 (0.27–1.17) 0.96 971 192 1.00
Q2 (1.17–1.63) 1.39 968 209 1.12 (0.92–1.38)
Q3 (1.63–2.28) 1.92 960 220 1.23 (1.00–1.50)
Q4 (2.28–11.02) 2.86 963 235 1.15 (0.93–1.41) 0.23
Model 3d
Q1 (0.27–1.17) 0.96 973 198 1.00
Q2 (1.17–1.63) 1.39 974 211 1.16 (0.96–1.42)
Q3 (1.63–2.28) 1.92 968 223 1.23 (1.01–1.49)
Q4 (2.28–11.02) 2.86 972 237 1.34 (1.09–1.63) 0.006
Women
Model 1b
Q1 (0–1.17) 0.97 1113 136 1.00
Q2 (1.17–1.66) 1.40 1112 139 1.06 (0.84–1.35)
Q3 (1.66–2.39) 1.98 1114 138 1.11 (0.87–1.41)
Q4 (2.39–13.97) 2.98 1113 181 1.58 (1.25–2.00) <0.0001
Model 2c
Q1 (0–1.17) 0.97 1110 136 1.00
Q2 (1.17–1.66) 1.40 1106 139 1.03 (0.81–1.32)
Q3 (1.66–2.39) 1.98 1101 137 1.04 (0.82–1.34)
Q4 (2.39–13.97) 2.98 1110 179 1.38 (1.08–1.75) 0.005
Model 3d
Q1 (0–1.17) 0.97 1113 136 1.00
Q2 (1.17–1.66) 1.40 1112 139 1.07 (0.85–1.37)
Q3 (1.66–2.39) 1.98 1114 138 1.07 (0.84–1.36)
Q4 (2.39–13.97) 2.98 1113 181 1.45 (1.14–1.83) 0.001
a
HR, 95% CI and P values were estimated by Cox proportional hazards models.
b
Model 1: Adjusted by Cox regression for age at blood draw, race/ethnicity (as a strata variable) and serum cholesterol levels.
c
Model 2: Adjusted by Cox regression for variables in Model 1, and further adjusted for history of cancer, cardiovascular diseases, diabetes, and 
hypertension and smoking related variables.
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d
Model 3: Adjusted by Cox regression for variables in Model 1, and further adjusted for C-reactive protein (log-transformed).
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